These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 37662925)

  • 1. Small molecular inhibitors for KRAS-mutant cancers.
    Wu X; Song W; Cheng C; Liu Z; Li X; Cui Y; Gao Y; Li D
    Front Immunol; 2023; 14():1223433. PubMed ID: 37662925
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current status and outlook of medical treatment for
    Xu W; Zhuo XL; Liu L; Zhao J; Lin XY; Fu GB
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):111-116. PubMed ID: 36781231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
    Reck M; Carbone DP; Garassino M; Barlesi F
    Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
    Parums DV
    Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Ceddia S; Landi L; Cappuzzo F
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012655
    [No Abstract]   [Full Text] [Related]  

  • 7. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sotorasib: A Review in KRAS G12C Mutation-Positive Non-small Cell Lung Cancer.
    Lee A
    Target Oncol; 2022 Nov; 17(6):727-733. PubMed ID: 36315377
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.
    Bungaro M; Novello S; Passiglia F
    Curr Treat Options Oncol; 2022 Dec; 23(12):1699-1720. PubMed ID: 36394791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS
    Hoshiyama H
    Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of
    Malhotra J; Nguyen D; Tan T; Semeniuk Iii GB
    Clin Adv Hematol Oncol; 2024 Mar; 22(2):67-75. PubMed ID: 38446474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for Targeting KRAS: A Challenging Drug Target.
    Wadood A; Ajmal A; Rehman AU
    Curr Pharm Des; 2022; 28(23):1897-1901. PubMed ID: 35524675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C-Mutant Non-Small Cell Lung Cancer.
    Arbour KC; Rizvi H; Plodkowski AJ; Hellmann MD; Knezevic A; Heller G; Yu HA; Ladanyi M; Kris MG; Arcila ME; Rudin CM; Lito P; Riely GJ
    Clin Cancer Res; 2021 Apr; 27(8):2209-2215. PubMed ID: 33558425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Concomitant KRAS mutations attenuate sensitivity of non-small cell lung cancer cells to KRAS G12C inhibition.
    Vaclova T; Chakraborty A; Sherwood J; Ross S; Carroll D; Barrett JC; Downward J; de Bruin EC
    Sci Rep; 2022 Feb; 12(1):2699. PubMed ID: 35177674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On target: Rational approaches to KRAS inhibition for treatment of non-small cell lung carcinoma.
    Lindsay CR; Garassino MC; Nadal E; Öhrling K; Scheffler M; Mazières J
    Lung Cancer; 2021 Oct; 160():152-165. PubMed ID: 34417059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS-G12C covalent inhibitors: A game changer in the scene of cancer therapies.
    Naim N; Moukheiber S; Daou S; Kourie HR
    Crit Rev Oncol Hematol; 2021 Dec; 168():103524. PubMed ID: 34800654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. KRAS-targeted therapy in the treatment of non-small cell lung cancer.
    Yun J; Nakagawa R; Tham K
    J Oncol Pharm Pract; 2023 Mar; 29(2):422-430. PubMed ID: 35938195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRAS-G12D mutation drives immune suppression and the primary resistance of anti-PD-1/PD-L1 immunotherapy in non-small cell lung cancer.
    Liu C; Zheng S; Wang Z; Wang S; Wang X; Yang L; Xu H; Cao Z; Feng X; Xue Q; Wang Y; Sun N; He J
    Cancer Commun (Lond); 2022 Sep; 42(9):828-847. PubMed ID: 35811500
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of immunotherapy in
    Davis AP; Cooper WA; Boyer M; Lee JH; Pavlakis N; Kao SC
    Immunotherapy; 2021 Aug; 13(11):941-952. PubMed ID: 34114474
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.